MCID: HDG002
MIFTS: 42

Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

MalaCards integrated aliases for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

Name: Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance 12 15
Hodgkin Disease 44 70
Hodgkin Lymphoma, Lymphocytic-Histiocytic Predominance 12
Hodgkin's Disease, Lymphocyte Predominance 12
Lymphocyte Rich Classical Hodgkin Lymphoma 70
Hodgkin Lymphoma, Lymphocyte-Rich 12
Lymphocyte Rich Hodgkin's Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8543
ICD9CM 34 201.4
MeSH 44 D006689
NCIt 50 C6913
SNOMED-CT 67 128799007
ICD10 32 C81.4
UMLS 70 C0019829 C1266194

Summaries for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

MalaCards based summary : Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance, also known as hodgkin disease, is related to lymphoma, hodgkin, classic and lymphoma, non-hodgkin, familial, and has symptoms including fever and night sweats. An important gene associated with Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance is FUT4 (Fucosyltransferase 4), and among its related pathways/superpathways are NF-kappaB Signaling and Mannose type O-glycan biosynthesis. The drugs Aldesleukin and Moxifloxacin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and t cells, and related phenotype is immune system.

Related Diseases for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Diseases related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 288)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 32.3 TNFRSF8 PTPRC BCL6
2 lymphoma, non-hodgkin, familial 29.9 TNFRSF8 PTPRC BCL6
3 b-cell lymphoma 29.8 TNFRSF8 PTPRC BCL6
4 lymphoproliferative syndrome 29.8 TNFRSF8 PTPRC BCL6
5 gastrointestinal lymphoma 29.7 TNFRSF8 BCL6
6 reticulum cell sarcoma 29.6 TNFRSF8 PTPRC
7 histiocytosis 29.6 TNFRSF8 PTPRC
8 lymphosarcoma 29.5 TNFRSF8 PTPRC BCL6
9 angioimmunoblastic t-cell lymphoma 29.5 TNFRSF8 BCL6
10 composite lymphoma 29.5 TNFRSF8 FUT4 BCL6
11 diffuse large b-cell lymphoma 29.3 TNFRSF8 PTPRC BCL6
12 leukemia, acute myeloid 29.2 TNFRSF8 PTPRC FUT4 BCL6
13 classic hodgkin lymphoma, lymphocyte-rich type 11.4
14 lymphoma, hodgkin, x-linked pseudoautosomal 11.4
15 lymphoproliferative syndrome 1 11.1
16 sarcoidosis 1 11.0
17 lymphoma, hodgkin, y-linked pseudoautosomal 11.0
18 hodgkin's paragranuloma 11.0
19 hodgkin's granuloma 11.0
20 lymphoma 11.0
21 hodgkin's lymphoma, lymphocytic depletion 10.2 TNFRSF8 FUT4
22 mediastinal malignant lymphoma 10.2 TNFRSF8 FUT4
23 pleural lipoma 10.2 TNFRSF8 FUT4
24 mediastinal gray zone lymphoma 10.2 TNFRSF8 FUT4
25 congenital granular cell tumor 10.2 FUT4 B3GAT1
26 ataxia and polyneuropathy, adult-onset 10.2
27 paranasal sinus lymphoma 10.2 TNFRSF8 BCL6
28 uterus leiomyosarcoma 10.1 TNFRSF8 FUT4
29 lung lymphoma 10.1 TNFRSF8 BCL6
30 t-cell/histiocyte rich large b cell lymphoma 10.1 TNFRSF8 BCL6
31 breast lymphoma 10.1 TNFRSF8 BCL6
32 anemia, autoimmune hemolytic 10.1
33 nephrotic syndrome 10.1
34 thrombocytopenia 10.1
35 hemolytic anemia 10.1
36 acquired immunodeficiency syndrome 10.1
37 uterine corpus sarcoma 10.1 TNFRSF8 FUT4
38 testicular infarct 10.1 TNFRSF8 PHYH
39 tracheal lymphoma 10.1 TNFRSF8 BCL6
40 pediatric lymphoma 10.1 TNFRSF8 BCL6
41 ataxia-telangiectasia 10.1
42 telangiectasis 10.1
43 purpura 10.1
44 adult lymphoma 10.1 TNFRSF8 BCL6
45 pleural empyema 10.1 TNFRSF8 BCL6
46 extraosseous ewings sarcoma-primitive neuroepithelial tumor 10.1 TNFRSF8 PTPRC
47 anaplastic large cell lymphoma 10.1
48 thrombocytopenia due to platelet alloimmunization 10.1
49 cerebellar degeneration 10.1
50 breast lipoma 10.1 TNFRSF8 PTPRC

Graphical network of the top 20 diseases related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:



Diseases related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Symptoms & Phenotypes for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

UMLS symptoms related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:


fever; night sweats

MGI Mouse Phenotypes related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.17 BCL6 FCRLA FUT4 JCHAIN PHYH PTPRC

Drugs & Therapeutics for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Drugs for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 412)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aldesleukin Approved Phase 2, Phase 3 85898-30-2, 110942-02-4
2
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
3
Chlorambucil Approved Phase 3 305-03-3 2708
4
Erythromycin Approved, Investigational, Vet_approved Phase 3 114-07-8 12560
5
Mesna Approved, Investigational Phase 3 3375-50-6 598
6
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
7
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 43805 6857599
8
Decitabine Approved, Investigational Phase 2, Phase 3 2353-33-5 451668
9
Azacitidine Approved, Investigational Phase 2, Phase 3 320-67-2 9444
10
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
11
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
12
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
13
Lenograstim Approved, Investigational Phase 3 135968-09-1
14
Epirubicin Approved Phase 3 56420-45-2 41867
15
Tacrolimus Approved, Investigational Phase 3 104987-11-3 6473866 445643 439492
16
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
17
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
18
Mycophenolic acid Approved Phase 3 24280-93-1 446541
19
tannic acid Approved Phase 3 1401-55-4
20
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
21
Etoposide Approved Phase 3 33419-42-0 36462
22
Ifosfamide Approved Phase 3 3778-73-2 3690
23
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
24
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
25
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
27
Carmustine Approved, Investigational Phase 3 154-93-8 2578
28
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166 2942
29
Vinblastine Approved Phase 3 865-21-4 241903 13342
30
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
31
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
32
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
33
Melphalan Approved Phase 3 148-82-3 4053 460612
34
rituximab Approved Phase 3 174722-31-7 10201696
35
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
36
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
37
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
38
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
39
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
40
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
41
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
42
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
43
Cortisone Experimental Phase 3 53-06-5 222786
44
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
45
Mitoguazone Investigational Phase 3 459-86-9
46 Antineoplastic Agents, Immunological Phase 3
47 interferons Phase 2, Phase 3
48 Interferon-gamma Phase 2, Phase 3
49 Norgestimate, ethinyl estradiol drug combination Phase 3
50 Cardiotonic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 747)
# Name Status NCT ID Phase Drugs
1 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
2 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Unknown status NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
3 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab vedotin
4 Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
5 A Prospective Multi-center Study for the Treatment of Chinese Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Using a Modified COG Strategy Recruiting NCT04726501 Phase 4
6 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Active, not recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
7 Protocol for a Randomized Phase III Study of the Stanford V Regimen, Compared With ABVD for the Treatment of Advanced Hodgkin's Disease Unknown status NCT00041210 Phase 3 ABVD regimen;Stanford V regimen;dacarbazine;doxorubicin hydrochloride;etoposide;mechlorethamine hydrochloride;prednisone;vinblastine sulfate;vincristine sulfate
8 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
9 Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
10 A Randomized Trial Of BEAM Plus PBSCT Versus Single Agent High-Dose Therapy Followed By BEAM Plus PBSCT In Patients With Relapsed Hodgkin's Disease Unknown status NCT00025636 Phase 3 carmustine;cisplatin;cyclophosphamide;cytarabine;dexamethasone;etoposide;melphalan;methotrexate;vincristine sulfate
11 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
12 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma Unknown status NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
13 Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
14 A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease Completed NCT00070187 Phase 2, Phase 3 carmustine;cyclosporine;cytarabine;etoposide;melphalan
15 A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease Completed NCT00302003 Phase 3 doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide;ifosfamide;vinorelbine tartrate;dexamethasone;etoposide phosphate;cisplatin;cytarabine
16 A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease Completed NCT00025259 Phase 3 Cisplatin;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate Liposome
17 Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) Completed NCT00443677 Phase 3 COPPEBVCAD vs BEACOPP vs ABVD
18 Double-blind, Randomized, Mono-center, Placebo-controlled Pilot Study to Investigate the Efficacy and Safety of Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed NCT00398411 Phase 3 moxifloxacin;placebo
19 Prophylactic Use of Filgrastim SD/01 In Patients With Hodgkin's Disease Receiving ABVD Chemotherapy Completed NCT00038558 Phase 3 Filgrastim SD/01;Adriamycin;Bleomycin;Vinblastine;DTIC
20 Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy Completed NCT01085058 Phase 2, Phase 3 lenograstim
21 A UKLG Randomised Trial of Initial Chemotherapy for Advanced Stage Hodgkins Disease Completed NCT00003421 Phase 3 ABVD regimen;chlorambucil;dacarbazine;doxorubicin hydrochloride;etoposide;prednisolone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
22 Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study Completed NCT00005578 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
23 RESPONSE DEPENDENT TREATMENT OF STAGES IA, IIA AND IIIA HODGKIN'S DISEASE WITH DBVE AND LOW DOSE INVOLVED FIELD IRRADIATION WITH OR WITHOUT ZINECARD: A PEDIATRIC ONCOLOGY GROUP PHASE III STUDY Completed NCT00002827 Phase 3 dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;vincristine sulfate
24 A Phase III Study of Radiotherapy or ABVD Plus Radiotherapy Versus ABVD Alone in the Treatment of Early Stage Hodgkin's Disease Completed NCT00002561 Phase 3 dacarbazine;doxorubicin hydrochloride;vinblastine
25 Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia in Recurrent or Refractory Non-Burkitt's, Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease Receiving DHAP (Dexamethasone, High-Dose Cytarabine and Cisplatin) Chemotherapy Completed NCT00039910 Phase 3 (PN-152,243)/ PN-196,444
26 A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease Completed NCT00003389 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine;Vincristine;Mechlorethamine;Etoposide;Prednisone;Cyclophosphamide
27 Randomized Trial of Subtotal Nodal Irradiation Versus Doxorubicin, Vinblastine and Subtotal Nodal Irradiation for Stage I-IIA Hodgkin's Disease Completed NCT00002495 Phase 3 doxorubicin hydrochloride;vinblastine
28 Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) - Safety Study in a General Autologous Transplant Population Completed NCT00838357 Phase 3 Generic = Plerixafor
29 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) on Anemia and Quality of Life in Children With Cancer Undergoing Myelosuppressive Chemotherapy Completed NCT00261677 Phase 3 epoetin alfa
30 First International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
31 HD12 for Advanced Stages Completed NCT00265031 Phase 3 Cyclophosphamide;Adriamycin;Etoposide;Procarbazine;Prednisone;Vincristine;Bleomycin
32 HD10 for Early Stages Completed NCT00265018 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC
33 A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment Completed NCT01854567 Phase 3
34 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant Completed NCT01100502 Phase 3 brentuximab vedotin;placebo
35 A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant (ASCT) Completed NCT01034163 Phase 3 Panobinostat;Placebo
36 Prospective Randomized Comparison of ABVD Versus BEACOPP Chemotherapy With or Without Radiotherapy for Advanced Stage or Unfavorable Hodgkin's Lymphoma (HL) Completed NCT01251107 Phase 3 Bleomycin;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Procarbazine;Prednisone;Doxorubicin;Bleomycin;Vinblastine;Dacarbazine
37 A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy Completed NCT00469729 Phase 2, Phase 3 StemEx®
38 HD11 for Intermediate Stages Completed NCT00264953 Phase 3 Adriamycin;Bleomycin;Vinblastine;DTIC;Etoposide;Procarbazine;Prednisone;Vincristine
39 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Completed NCT01188798 Phase 3 Methotrexate;Pentostatin
40 Randomized Phase III Study of a Treatment Driven by Early PET Response Compared to a Treatment Not Monitored by Early PET in Patients With Ann Arbor Stage III-IV or High Risk IIB Hodgkin Lymphoma Completed NCT01358747 Phase 3 BEACOPPesc;BEACOPPesc - ABVD - PET2
41 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
42 Early Salvage With High Dose Chemotherapy and Stem Cell Transplantation in Advanced Stage Hodgkin's Lymphoma Patients With Positive PET After Two Courses of ABVD (PET-2 Positive) and Comparison of RT Versus no RT in PET-2 Negative Patients Completed NCT00784537 Phase 2, Phase 3 ABVD;ABVD and Radiotherapy
43 HD17 for Intermediate Stages - Treatment Optimization Trial in the First-Line Treatment of Intermediate Stage Hodgkin Lymphoma Completed NCT01356680 Phase 3 BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone);ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)
44 HD18 for Advanced Stages in Hodgkins Lymphoma Completed NCT00515554 Phase 3 Rituximab;BEACOPP escalated
45 First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia Recruiting NCT04638790 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine;Etoposide;Doxorubicin;Cyclophosphamide;Vincristine;Dexamethasone;Dacarbazine
46 Opioid-Sparing Pain Treatment In Myeloma And Lymphoma Patients Undergoing High-Dose Chemotherapy (OPTIMAL-HiChemo): Randomized Controlled Trial Recruiting NCT04459416 Phase 3 opioid
47 A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Recruiting NCT03907488 Phase 3 Brentuximab Vedotin;Dacarbazine;Doxorubicin Hydrochloride;Vinblastine Sulfate
48 A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL). Recruiting NCT03159897 Phase 3 Doxorubicin;Bleomycin;Vinblastine;Dacarbazine
49 A Multicenter, Open-Label, Randomized Controlled Phase 3 Study of Tislelizumab Monotherapy Versus Salvage Chemotherapy in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Recruiting NCT04486391 Phase 3 Tislelizumab;Salvage Chemotherapy
50 A Randomized,Open-label Phase III Study of Camrelizumab (SHR-1210) vs. Investigator's Choice of Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Recruiting NCT04342936 Phase 3 Camrelizumab;Investigator's choice of Chemotherapy

Search NIH Clinical Center for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Ifosfamide
Lomustine
Mechlorethamine
Mechlorethamine hydrochloride
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vinblastine
Vinblastine Sulfate
Vincristine
Vincristine Sulfate
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: hodgkin disease

Genetic Tests for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Anatomical Context for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

MalaCards organs/tissues related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

40
Bone Marrow, Bone, T Cells, Lung, Liver, Breast, Thyroid

Publications for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Articles related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance:

(show top 50) (show all 1470)
# Title Authors PMID Year
1
Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies. 61
33794925 2021
2
Secondary cutaneous involvement by direct extension in high-grade B-cell lymphomas. 61
32639608 2021
3
Non-classical secretion of a type I L-asparaginase in Bacillus subtilis. 61
33757855 2021
4
Prevalence of and factors influencing vitamin D deficiency in paediatric patients diagnosed with cancer at northern latitudes. 61
33528842 2021
5
Outcome and Prognostic Factors of Childhood Hodgkin Disease: Experience From a Single Tertiary Center in Thailand. 61
32590417 2021
6
Primary bone lymphoma: Clinical presentation and therapeutic considerations. 61
33083218 2020
7
Intense Increased 18F-FDG Uptake of Masticator Muscles After Cocaine Use. 61
32969905 2020
8
Incidence of haematological malignancies in adults in Szabolcs-Szatmár-Bereg county, Hungary. Analysis of data of a 36-year period 61
32804670 2020
9
A case of metachronous peripheral T-Cell non-Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin. 61
32884752 2020
10
Outcome at the end of treatment of patients with common and curable childhood cancer types in Blantyre, Malawi. 61
32391955 2020
11
Late mortality in survivors of childhood cancer in Hungary. 61
32612167 2020
12
Use of checkpoint inhibitors in gray zone lymphoma. 61
32589932 2020
13
Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. 61
32098890 2020
14
The physiological and pathological roles and applications of sialyl Lewis x, a common carbohydrate ligand of the three selectins. 61
32062824 2020
15
Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease. 61
32143684 2020
16
[Paraneoplastic subacute degeneration of the cerebellum in non-small cell lung cancer and positive anti-Tr3 antibodies]. 61
31900515 2020
17
Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact. 61
32457824 2020
18
Multidetector computed tomography evaluation of synchronous lymphoma and other solid malignancies. 61
32362610 2020
19
Pathfinders in oncology from the first clinical use of single-agent chemotherapy to the introduction of mammography. 61
33095913 2020
20
Primary diffuse large B-cell lymphoma of mandible masquerading as a toothache. 61
31792469 2020
21
Cancer Risk in Klippel-Trenaunay Syndrome. 61
31045469 2019
22
[Autoimmune hemolytic anemia and immune thrombocytopenia associated with Hodgkin disease: Retrospective monocentric study]. 61
31668883 2019
23
The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 French hematology departments. 61
30458690 2019
24
Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation. 61
31707719 2019
25
Epithelial cell infection by Epstein-Barr virus. 61
31584659 2019
26
Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation. 61
31170519 2019
27
Characteristics and Survival Outcomes of Children With Hodgkin Lymphoma Treated Primarily With Chemotherapy. 61
31033793 2019
28
Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. 61
30322329 2019
29
Prevalence of deaths in a cohort of girls and women with cryopreserved ovarian tissue. 61
30770545 2019
30
Hepatic Manifestations of Lymphoproliferative Disorders. 61
30947878 2019
31
Primary adrenal Hodgkin lymphoma. 61
30899496 2019
32
Proton beam therapy in pediatric oncology. 61
30531222 2019
33
Acrokeratosis Can Be a Warning Sign of an Underlying Malignancy. 61
31157185 2019
34
Interest of FDG-PET in the Management of Mantle Cell Lymphoma. 61
31024918 2019
35
Unusual occurrence of avascular necrosis with bilateral involvement and ankylosing spondylitis, meningioma and Hodgkin lymphoma. 61
31912115 2019
36
Presentation and Outcomes of Childhood Cancer Patients at Uganda Cancer Institute. 61
31205984 2019
37
Paracoccidioides brasiliensis Infection Mimicking Recurrent Hodgkin Lymphoma: A Case Report and Review of the Literature. 61
29476307 2018
38
Predictive Value of FDG PET/CT Versus Bone Marrow Biopsy in Pediatric Lymphoma. 61
30358625 2018
39
Vaccine-induced immune thrombocytopaenia purpura in autologous haematopoietic stem cell transplantation. 61
30647224 2018
40
Novel Pilot Curriculum for International Education of Lymphoma Management Using E-Contouring. 61
30241149 2018
41
Long-term risk of cardiovascular mortality in lymphoma survivors: A systematic review and meta-analysis. 61
30112841 2018
42
Bone loss and hematological malignancies in adults: a pilot study. 61
29549514 2018
43
Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies. 61
29616457 2018
44
F-18 FDG PET-CT Versus Contrast Enhanced CT in Detection of Extra Nodal Involvement in Patients with Lymphoma. 61
29962712 2018
45
A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency. 61
29644723 2018
46
Is Carotid Stiffness a Possible Surrogate for Stroke in Long-term Survivors of Childhood Cancer after Neck Radiotherapy? 61
30018516 2018
47
l-Asparaginase: a feasible therapeutic molecule for multiple diseases. 61
29872609 2018
48
FDG Accumulation in the Lumen of the Gallbladder Without Related Pathology. 61
29485432 2018
49
Granulomatous Lymphangitis Masquerading as Relapsed Hodgkin Disease on FDG PET/CT. 61
30042982 2018
50
Evidence for the association of Epstein-Barr Virus in breast cancer in Indian patients using in-situ hybridization technique. 61
28557251 2018

Variations for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Expression for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Search GEO for disease gene expression data for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance.

Pathways for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Pathways related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.65 TNFRSF8 PTPRC BCL6
2 9.98 FUT4 B3GAT1

GO Terms for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

Cellular components related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell periphery GO:0071944 8.62 PTPRC FUT4

Biological processes related to Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of tumor necrosis factor production GO:0032760 9.16 TNFRSF8 PTPRC
2 B cell differentiation GO:0030183 8.96 PTPRC BCL6
3 positive regulation of B cell proliferation GO:0030890 8.62 PTPRC BCL6

Sources for Hodgkin's Lymphoma, Lymphocytic-Histiocytic Predominance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....